Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Vaccinia × Sorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 70 Carcinoma, Renal Cell 33 Neoplasms 31 Liver Neoplasms 20 Carcinoma 6 Thyroid Neoplasms 4 Neoplasm Metastasis 4 Melanoma 4 Carcinoma, Non-Small-Cell Lung 4 Kidney Neoplasms 3 Breast Neoplasms 3 Vaccinia 1 Stomach Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Glandular and Epithelial 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Lymphoma 1 Liver Diseases 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Insulin-Like Growth Factor I, Resistance To 1 Hypophosphatemia 1 Hepatitis C 1 Hepatitis B 1 Glioblastoma 1 Digestive System Neoplasms 1 Digestive System Diseases 1 Colorectal Neoplasms 1 Carcinoma, Medullary 1

Interventions

pembrolizumab 2 Docetaxel 2 Cisplatin 2 Bevacizumab 2 130-nm albumin-bound paclitaxel 2 taxane 1 liposomal doxorubicin 1 durvalumab 1 cemiplimab 1 atezolizumab 1 Sorafenib 1 Pemetrexed 1 Paclitaxel 1 Nivolumab 1 Irinotecan 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Drug Therapy 1 Biosimilar Pharmaceuticals 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02562755 2020-12-16

PHOCUS

SillaJen, Inc.

Phase 3 Completed

459 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡